However, ~20% of patients with ER+/HER2− breast cancer are intrinsically resistant to endocrine therapy and ~40% of patients with ER+/HER2− breast cancer acquire resistance over time (14, 16, 17). This evidence concerns the gene ESR1 and breast carcinoma.